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Abstract
Aim To perform a baseline survey on condition-specific information access among patients/parents/caregivers with rare
endocrine disorders (RD) in Europe.
Methods Electronic invitation to participate in a survey (19 questions) was sent to 120 patient advocacy groups (PAGs), and
further distributed to 32 European countries.
Results A total of 1138 respondents from 22 countries (74% women), aged between 1 year (parents) and 70 years,
participated. The Netherlands, France, Germany, Italy and France had highest participation rates. All Main Thematic
Groups (MTGs) were represented; the adrenal (32%), pituitary (26%) and thyroid (22%) were the most common. The
majority of the respondents got information from their endocrinologist (75%), PAGs (37%) and expert reference centre
(22%); 95% received information in their mother tongue. Leaflets (70%), infographics (65%), webinars (60%) and
Internet films (55%) were preferred ways of learning. Respondents relied mostly on materials by PAGs and alliances
(79%), rather than from specific international RD sites (15%). Fifty-six percent used Facebook, and 37% other social
media, with a significant age difference (<40/>40 years) among non-users, 19% vs. 36%, p < 0.0001. Of all, 685 answered
questions on informational materials for children−79% wanted materials that can be used by the children themselves.
There was significant age difference (<40 years/>40 years) in the willingness to help create new educational materials;
49% vs. 34%, p < 0.001.
Conclusions Our current patient information access survey provides a sound basis for further planning and execution of
educational and teaching activities by Endo-ERN.
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Background
European Reference Networks (ERNs) for rare disorders
(RD) are based on the directive 2011/24/EU of the Eur-
opean Parliament governing the right of European citizens
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to have access to cross-border healthcare (https://eur-lex.
europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:088:
0045:0065:en:PDF). ERNs are virtual networks linking
expert reference centres across Europe. Operation started in
2017 with the main goal to exchange knowledge, resources
and competence to tackle the rare conditions paradigm, and
secure rapid improvement of RD care. At the same time,
ERNs are a 5 year pilot project to test the above hypothe-
sized goal in real life conditions that are still so diverse in
the European Union and even more diverse globally. The
process was inspired by the patients in the early 1980s. A
complex development of care and policies at national level
started followed by organizational and hierarchical mea-
sures at the European level, and lead to the idea of creating
virtual reference networks [for review, see [1]]. Participa-
tory approach to patients is a must from the very beginning.
At the very heart of the idea is the strive of patients and their
collective European patient advocacy group representatives
(ePAGs) to decrease time to diagnosis, to improve treatment
and follow-up, and to increase support of RD patients
working together with the medical community [2–4]. One
of the continuous efforts of the ePAGs is to measure
patients and their representatives (parents/caregivers/stake-
holders) opinion (https://www.eurordis.org/content/current-
surveys).
Timely and quality information and education is impor-
tant for patient empowerment [5], and coping with the sense
of social isolation receiving a rare diagnosis is crucial for
better outcome [6]. PAG representatives promote knowl-
edge generation (research and education) most successfully
through partnership models [7] thus facilitating acceleration
of quality improvement of RD healthcare. From the
beginning, every ERN was free to decide how to organize
and secure their participation.
The European Reference Network on Rare Endocrine
Conditions (Endo-ERN) unites 86 health care providers
(HCPs) from 27 European countries, currently including
the UK. The core principles are equality between paedia-
tric and adult patients, between paediatric and adult health
care professionals, and equal representation (adult and
paediatric) of ePAGs. Endo-ERN promotes diversity and
strives to achieve cross-borders health equality and better
care for patients with endocrine rare conditions throughout
life-span.
The organizational structure is based on eight main the-
matic groups (MTGs), namely: MTG1 Adrenal; MTG2
Disorders of Calcium and Phosphate Homeostasis; MTG3
Genetic Disorders of Glucose and Insulin Homeostasis;
MTG4 Genetic Endocrine Tumor Syndromes; MTG5
Growth and Genetic Obesity Syndromes; MTG6 Pituitary,
MTG7 Sex Development and Maturation, and MTG8
Thyroid. Every MTG strived to have four chairs—a pae-
diatric, and an adult professional, and two ePAG
representatives, favorably a paediatric and an adult one. The
structure is complemented with five “horizontal” Work
Packages (WPs). Work package 1 (WP1) Education &
Training has the same type of governance as described
above consisting of four chairs, and major tasks are to
collect, qualitatively assess, align and boost education and
teaching in the field of rare endocrine diseases.
Education and training in the field of rare endocrine
diseases is aiming at health care professionals, patients,
stakeholders, and society. Apparently, it could have
different dimensions and focus based on the audience [8].
In order to plan further actions how to generate knowl-
edge within and beyond the Network, the first step was to
map the situation at baseline. Health professionals’
relevant education and training resources were evaluated
(Iotova et al., submitted), and for patients, the most
relevant current informational sources were evaluated
with view to use these for further knowledge generation
and dissemination.
The aim of this study was to assess which informational
sources patients/parents/caregivers with rare endocrine
conditions in Europe preferred at the time of initiation of
Endo-ERN.
Materials and methods
A survey was prepared (EUSurvey, https://ec.europa.eu/
eusurvey/home/about) consisting of 12 main questions,
some of which had subsections (overall 19 questions).
It was entirely constructed by the WP1 ePAG Co-chairs
(M.B. and P.B.), who are very experienced in the patient
advocacy field [9].
Data collection and analysis
The survey began distribution on 09/03/2018 and the last
response was received on 22/05/2018.
An invitation e-mail was sent to 120 patient advocacy
groups (PAGs) in 20 European countries, and then re-
distributed via Facebook, Twitter, and Messenger to cover
a total of 32 countries. To facilitate participation, the sur-
vey was offered for translation to patients/advocacy groups
in all European countries, and was thereafter translated in
seven European languages (Bulgarian, Dutch, English,
French, German, Italian, Spanish), with the voluntary work
of patients and with the help of local HCP Network
representatives. At present, these documents and links to
the individual patient groups are collected on the CIR-
CABC Platform of the EU, sorted by country as well as by
affiliation to the individual MTGs. The survey explored
the use of informational resources among endocrine RD
patients/parents/caregivers and relevant stakeholders in
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order to enable the Network to develop these further in the
next 3 years of its development.
Informed consent was actively sought by every partici-
pant by asking them whether they are happy to continue the
survey after initial explanation about survey’s aim and
scope. By ticking the “yesˮ box all participants agreed to
participation and to continue the survey.
Analysis was done automatically with the DIGIT-
EUROSURVEY system. Statistical significance was asses-
sed by Chi-square test. Level of significance was set at
p < 0.05.
Results
Characteristics of the study cohort
Participating countries
A total of 1138 respondents participated, the majority from
five countries whose ePAGs had representatives at the
Network—The Netherlands, France, Germany, Italy and
UK—987 (16% of all addressed countries, 87% of all
answers) (see supplementary Table 1). Fewer than five
responses came from 28% of the participating countries. No
answers were received from patients from Bosnia and
Herzegovina, Croatia, Cyprus, Czech Republic, Estonia,
Latvia, Lithuania, Poland, Macedonia and Slovak Republic
(31% of all surveyed countries).
Gender, age distribution, and participation according to
MTG affiliation
(Figure 1) Respondents answered in their role as a patient or
a parent/caregiver on behalf of the patient. Most participants
were aged between 41 and 70 years (63%), and 74% were
women. Two-thirds of the participants were affiliated to 3 of
the 8 Endo-ERN MTGs.
Sources of information
Language
According to 95% of the respondents, patients primarily
seek and receive information in their native language.
Primary source of information
(Figure 2a) Most participants received information from
their endocrinologist (75%), followed by PAGs (37%) and
expert reference centres (22%).
Preferred ways of learning about rare endocrine disorders
On a Likert scale, most respondents considered leaflets as
very helpful (70%), followed by infographics (65%),
webinars (60%) and Internet films (55%).
Current access to information
Regarding currently used sources, leaflets (34%) and
“other” (unspecified) sources were equally common (34%),
followed by Internet movies (22%). Although infographics
were ranked as a highly preferred source (78%), only 13%
currently use infographics, while 18% participated in
webinars. There was no statistically significant difference in
the use of any of these sources by age.
Reliability
Patients/respondents confined predominantly in materials
published by ePAGs and alliances (79%). The relative share
of the materials provided by reference centres was 26%,
while very few mentioned medical journalists (7%) or
pharmaceutical companies (7%) as their informational
source (Fig. 2b). These findings are further supported by the
data on currently used websites (Fig. 3). The majority, 49%,
used websites of the national PAGs, followed by various
official medical websites. Specifically, designed patient
sites for RD such as Eurordis, Orphanet, and others were
not among preferred choices, in total 22%. Currently, 20%
of patients/parents/caregivers did not use any site, while
44% acquire information as a one-way off activity, without
any further updates.
Social media
Half of the respondents, 56%, were active on Facebook,
almost 17% used Whatsapp, and the others used Twitter,
Instagram or other forms of social media (SM). In contrast,
30% did not use any of the SM channels listed in the survey












































Fig. 1 Distribution of patients according to their MTG affiliation
within the Endo-ERN
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When asked whether they would impart general infor-
mation about their disorder via SM, 44% considered this
very unlikely/unlikely, while 42% responded with “very
likely/likely”. Further analysis by age showed that partici-
pants <40 years of age (n= 375) were more likely to use
SM than those >40 years of age (n= 763) (Fig. 4). This
result was further supported by the significantly higher age
of complete non-users of SM, 19% of respondents
<40 years, vs. 36% >40 years (χ2= 35.07, p < 0.0001).
Educational materials for children
A total of 685/1138 participants responded to survey
questions regarding the need for informational materials
for children. The vast majority (79%) expressed their wish
for special materials that can be used by the children
themselves.
Satisfaction with available information and
willingness to help create new materials
On a Likert scale, in the whole group 57% were very
satisfied/somewhat satisfied with the available information,
while 28% were very dissatisfied/dissatisfied. The analysis
by age of the participants (</>40 years) showed that those
<40 years were much more dissatisfied with available
informations (χ2= 9.19, p= 0.002).
When further asked whether they would participate in
creating new materials, 61% responded that they would not
want to be engaged in such activities. However, when
stratified by age, 49% of people <40 years would engage in
creating new informational materials vs. 34% of people
>40 years (χ2= 22.89, p < 0.0001).
Discussion
Today, patient education is recognized as an essential tool
for improving care of patients with RD [10]. Recently,
Pelentsov et al. [11] defined educational needs of parents of
children with RD (62%) as the second priority after social
needs (72%). Our baseline Endo-ERN information access
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Fig. 2 Answers to the question
“Where do you get the
information about the rare
disease?” (a) and “Who
published the information?” (b)
(more than one answer was
possible)
Fig. 3 The distribution of the Internet websites currently used by
patients with rare endocrine diseases
Fig. 4 Distribution of social media users among patients within Endo-
ERN by age
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knowledge, the largest attempt so far to capture patient
educational access data in Europe. This paper provides
evidence that information access has developed lately to a
large extent, especially as a powerful lever of patient
empowerment [12, 13]. This is probably a result of the
concerted action in the recent decades to unite RD patients
and create a shared platform for common goals.
The development of the Internet is acknowledged as a
major contributor to these goals [14]. In practice, it cur-
rently reaches all communities and assures better access to
information [6, 15]. The level of inclusion of patients within
structures called on stage to secure addressing needs and
raising the patients’ voice whenever their health care, needs
and rights are concerned is very diverse. A third of the
countries in Europe, the majority of which are European
Union member states, seem not to be active and not a single
patient voice responded from these countries. Furthermore,
fewer than five answers were received from another 45% of
countries. Thus, this study is not representative for the
whole of Europe but rather represents the more organized
and professionally advanced parts of it, and for ePAGs that
already have reached a certain level of maturity. The same
pattern is seen among participants in other RD surveys
(https://www.eurordis.org/voices. Accessed Oct 20th,
2020). This shows that Endo-ERN needs to invest more
effort and planned action to reach out to the still silent
patient communities in these countries.
It was of no surprise that most of the survey respondents
were female. This has been replicated many times in dif-
ferent previous studies in rare patient communities
[6, 15, 16]. The study captured primarily a mature age
cohort of both patients and parents/caregivers of patients
with RD. Since new informational technologies have
emerged at a fast rate in the last decade, and because we
aimed primarily to collect information to plan future action,
further analysis based on age was required.
As a uniform finding, patients/parents/caregivers obtain
information about their disease from their primary doctor—
the endocrinologist. Importantly, the respondents rank
ePAGs second and expert reference centres third. This
underlines the important role of ePAGs, specifically of their
professional development and maturation as lay-men-
experts, since their first emergence more than 25 years ago
[1] and the quality of information they provide [17]. At the
very beginning of the Endo-ERN this finding also impor-
tantly shaped Network outreach and efforts to bolster
knowledge distribution.
A unanimous result, that was independent of age, was the
current preference of leaflets as a primary educational
resource, as well as the providing doctor/expert centre as the
informational source, followed by Internet films and webi-
nars. We assume that the latter is connected to the many
useful and well-designed materials made available through
the activity of health care professionals and the ePAGs that
are already reaching patients (Endo-ERN current collection
at https://endo-ern.eu/patients/patient-information-materia
ls/) [18]. A prerequisite of success is the availability in
the native language, still a major preference among patients
according to respondents of the current survey (95%).
The result on confidence in information provided by the
PAGs are also very important. It not only tells how well
developed they are—at least in some parts of Europe—but
also shows that one of the primary goals of the RD
movement—overcoming social isolation and seeking new
ways for better treatment and care, is at least partially ful-
filled. It is evident that the distribution of education and
know-how at the national level, and in local languages as
well as actively attracting leadership requires further top-
down action [7]. Other challenges to tackle are the passive
attitude of a significant number of patients/parents/care-
givers to the RD movement, and the paucity of continuous
and sustainable education [19].
The results of the assessment of attitudes to and use of
SM in the current survey are intriguing. The preference for
exchanging general information about the disorder via SM,
on the one hand, and the aversion to SM on the other hand,
were equally common in our study cohort. However, the
majority of those who would not share information
through SM were patients/parents/caregivers >40 years of
age (χ2= 35.07, p < 0.0001). Younger respondents use SM
significantly more, but are at the same time more dis-
satisfied with the available information in general. This
finding, as well as the predominance of female respon-
dents, is in line with those of other studies. DeHoff et al.
[6] found that nearly all women aged 18–29 in the USA
used SM, and find social support there [20]. Social media
are expected to become more and more useful for diag-
nosing rare disorder patients [21].
In the future, to achieve faster patient outreach, espe-
cially to younger ones, more educational content of suffi-
cient quality could be distributed through SM to serve not
only as an educational and social support resource but also
for sharing best practices [10]. SM could also serve as
means of studying RD per se [2, 19], following examples
from other more common disorders [22]. The major source
should be the PAGs’ tools in the local languages since
patients mostly need peer support with easy access to reli-
able information that is meaningful to them [11]. An
important goal is the development of a collection of specific
education and training materials from the MTGs. Of note,
younger patients/parents/caregivers are not only in need of,
but also are more inclined to engage in creating new
materials. Further attention has to be invested in patients
who currently do not use any informational source in order
to create ways of reaching out and helping them as well.
Social media seems to hold great potential as it is a
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combination of emotional and informational support [6]. A
tested tool is the wider distribution of positive examples and
political empowerment of RD PAGs [23, 24].
Strengths and shortcomings
Strengths of the study include the large number of partici-
pants reached through ePAGs’ channels, robust results, the
comprehensive though brief nature of the survey, and the
local input for translation by patients´ advocates. As a
baseline collective action, the study played an important
role in consolidating and mapping the roles of ePAGs
representatives at Endo-ERN.
As stated above, the current survey does not represent the
entire RD endocrine community in Europe, as specifically
patients from Eastern European were underrepresented.
Most likely, this reflects combinations of language barriers,
different levels of maturity of professional patient organi-
zations, if present at all, distrust in/lack of acceptance of EU
policy, cultural differences, and other, as yet unidentified
factors. The survey was not constructed to capture the
degree of use of resources or the level of information of
patients, or the differences between achievements of ePAGs
in informing their membership/followers.
In conclusion, our current patient information access
survey provides sound evidence for further planning
and execution of educational and teaching activities by
Endo-ERN.
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